Receptor radiopharmaceuticals

  • Azuwuike Owunwanne
  • Mohan Patel
  • Samy Sadek


Receptors are macromolecules with two distinct characteristics:
  • the ability to recognize and selectively bind ligands with similar structures;

  • the ability to initiate a biologic response when an appropriate ligand is bound to it.


Dopamine Receptor Receptor Site Islet Cell Carcinoma Dopamine Recep Radioactive Ligand 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kung, H.F., Sangren, P., Kung, M.-P. et al. (1989) In vitro and in vivo evaluation of [123I] IBZM: A potential CNS D-2 dopamine receptor imaging agent. J. Nucl. Med., 30, 88–92.Google Scholar
  2. 2.
    Seibyl, J.P., Woods, S.W., Zoghbi, S.S. et al. (1992) Dynamic SPECT imaging of dopamine D2 receptors in human subjects with iodine-123-IBZM. J. Nucl. Med., 33, 1964–71.Google Scholar
  3. 3.
    Toyama, H., Ichise, M., Ballinger, J.R. et al. (1993) Dopamine D2 receptor SPECT imaging: Basic in vivo characteristics and clinical applications of 123I-IBZM in humans. Ann. Nucl. Med., 7, 29–38.CrossRefGoogle Scholar
  4. 4.
    Reichlin, S. (1983) Somatostatin. N. Engl. J. Med., 309, 1495–1501, 1556-63.CrossRefGoogle Scholar
  5. 5.
    Maziere, B., Maziere, M. (1990) Where have we got to with neuroreceptor mapping of the human brain? Eur. J. Nucl. Med., 16, 817–35.CrossRefGoogle Scholar
  6. 6.
    Kilbourn, M.R. and Zalutsky, M.R. (1985) Research and clinical potential of receptor based radiopharmaceuticals. J. Nucl. Med., 26, 655–62.Google Scholar
  7. 7.
    Kung, H.F., Kasliwal, R., Pan, S. et al. (1988) Dopamine D-2 receptor imaging radiopharmaceutical: synthesis, radiolabeling, and in vitro binding of (R)-(+)-and (S)-(−)-3-iodo-2-hydroxy-6-methoxy-N-[(l-ethyl-2-pyrrolidinyl) methyl] benzamide. J. Med. Chem., 31, 1039–43.CrossRefGoogle Scholar
  8. 8.
    Kohler, C., Hall, H. and Gawell, L. (1986) Regional in-vivo binding of the substituted benzamide [3H]-eticlopride in the rat brain: evidence for selective labelling of dopamine receptors. Eur. J. Pharmacol, 120, 217–26.CrossRefGoogle Scholar
  9. 9.
    Hall, H. and Wedel, I. (1986) Comparisons between the in-vitro binding of two substituted benzamides and two butyrophenones to dopamine-D-2 receptors in the rat striatum. Acta Pharmacol. Toxicol., 58, 368–73.CrossRefGoogle Scholar
  10. 10.
    Product Information (1993) 123I-IBZM imaging of dopamine D2 receptors in the brain by SPECT. Cygne, Eindhoven University of Technology, The Netherlands.Google Scholar
  11. 11.
    Kung, H.F., Guo, Y.-Z., Billings, J. et al (1988) Preparation and biodistribution of [125I] IBZM: a potential CNS D-2 dopamine receptor imaging agent. Nucl. Med. Biol, 2, 195–201.Google Scholar
  12. 12.
    Kung, H.F. (1986) Brain radiopharmaceuticals, in Advances in Radiopharmaceuticals, Vol. 1 (ed. A. Fritzberg) CRC Press, Boca Raton, FL, pp. 21–10.Google Scholar
  13. 13.
    Kvols, L.K., O’Dorisio, T., Patel, S. et al. (1989) Pharmacokinetic studies of SMS 201-995 (Sandostatin) comparing two subcutaneous injection sites. J. Natl. Cancer Inst., 81, 1926–29.CrossRefGoogle Scholar
  14. 14.
    Bauer, W., Briner, U., Doepfner, W.S. et al. (1982) SMS 201-995; a very potent and selective octapeptide analogue of somatostatin with very prolonged action. Life Sci., 31, 1133–41.CrossRefGoogle Scholar
  15. 15.
    Reubi, J.C., Kvols, L.K., Krenning, E. and Lamberts, S.W. (1990) Distribution of somatostatin in normal and tumour tissue. Metabolism, 30 (Suppl.2), 78–81.CrossRefGoogle Scholar
  16. 16.
    Reubi, J.C., Hacki, W.H., Lamberts, S.W. (1987) Hormone-producing gastrointestinal tumours contain high density of somatostatin receptors. J. Clin. Endocrinol. Metab., 65, 1127–34.CrossRefGoogle Scholar
  17. 17.
    Reubi, J.C., Kvols, L.K., Nagorney, D.M. et al. (1990) Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinoma. Cancer Res., 50, 5969–77.Google Scholar
  18. 18.
    Bakker, W.H., Albert, R., Bruns, C. et al. (1991) [111In-DTPA-D-Phe’l-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: Synthesis, radio-labeling and in vitro validation. Life Sci., 49, 1583–91.CrossRefGoogle Scholar
  19. 19.
    Product Information (1992) Somatostatin receptor imaging using Octreoscan. Mallinckrodt Medical, Petten, The Netherlands.Google Scholar
  20. 20.
    Krenning, E.P., Bakker, W.H., Kooij, P.P.M. et al. (1992) Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-tyr-3-octreotide. J. Nucl. Med., 33, 652–58.Google Scholar
  21. 21.
    Bakker, W.H., Krenning, E.P., Reubi, J.C. et al. (1991) In vivo application of [111In-DTPA-D-Phel-octreotide for detection of somatostatin receptor positive tumors in rats. Life Sci., 49, 1593–601.CrossRefGoogle Scholar

Copyright information

© Azuwuike Owunwanne, Mohan Patel and Samy Sadek 1995

Authors and Affiliations

  • Azuwuike Owunwanne
    • 1
  • Mohan Patel
    • 2
  • Samy Sadek
    • 3
  1. 1.Department of Nuclear Medicine, Faculty of MedicineKuwait UniversityKuwait
  2. 2.Kuwait Central Radiopharmacy Kuwait Cancer Control CenterMinistry of Public HealthKuwait
  3. 3.Department of Nuclear Medicine Faculty of MedicineKuwait UniversityKuwait

Personalised recommendations